Navigation Links
Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D
Date:1/9/2012

ROCKVILLE, Md. and BEIJING, Jan. 10, 2012 /PRNewswire-USNewswire/ -- The global fight against the tuberculosis epidemic receives a boost today as Aeras and the China National Biotec Group (CNBG) announce that they have reached final agreement to jointly develop new tuberculosis (TB) vaccines. The agreement between the leading non-profit developer of TB vaccine candidates and the largest biotechnology corporation in China signals a commitment by both to engage and strengthen the role of China in the fight against one of the world's deadliest infectious disease killers.

Xiaoming Yang, President of CNBG, said of the agreement: "CNBG has a great deal of expertise and energy to invest in this partnership. Not only is TB a public health crisis of the developing world, it is also a priority health issue here in China. We look forward to working with our counterparts at Aeras to develop new TB vaccines that will help stop tuberculosis in all corners of the world."

Multiple research institutes operating under the umbrella of CNBG will engage with Aeras on a strategy focused on the joint development, manufacturing and distribution of affordable new TB vaccines for use globally. The agreement spans all aspects of TB vaccine development – from vaccine discovery to pre-clinical research to clinical research to manufacturing – and positions CNBG as a major emerging player in the TB vaccine field.

Bacille Calmette-Guerin (BCG), the only currently-licensed TB vaccine, does not prevent pulmonary TB, the most common form of the disease. As part of this collaboration, Aeras will license its recombinant BCG (rBCG) platform – which aims to improve upon the current TB vaccine – and other technologies to CNBG. The groups will jointly develop novel TB vaccines using the rBCG platform and other technologies provided by Aeras or CNBG's research institutes. A variety of candidate booster vaccines will be engineered to match the new constru
'/>"/>

SOURCE Aeras
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NxStage Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
2. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
3. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
4. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
5. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
6. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
7. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
10. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
11. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... 16 Exiqon today announces,the adoption of the ... the company,s commitment to expanding its business to ... guide treatment,decisions in oncology., Exiqon is pleased ... for their,clinical laboratory diagnostics business, Exiqon Diagnostics. This,progressive ...
... Oct. 16 Gaining a first-cycle,approval for a ... $640,million in incremental revenue on average, according to ... of PAREXEL International (Nasdaq: PRXL ),and leading ... device industries. According to the PAREXEL Consulting,analysis, 60 ...
... of carbon nanotubessorted by centrifuge for lengthmaterials scientists ... (NIST) have made some of the most precise ... mats of nanotubes become transparent, conducting sheets. Their ... relatively homogeneousnot overly short, but uniform in length ...
Cached Biology Technology:Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc. 2Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc. 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5Paperwork: Buckypapers clarify electrical, optical behavior of nanotubes 2
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... or simply cli-fi, is a newly coined term for novels ... New research from University of Copenhagen shows how these fictions ... the potential consequences of climate change and imagine other living ... data on changes in the atmosphere; it is also a ... books we read and the films we see. And there ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... (May 23, 2008) A study led by Gregg ... Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, ... the direct thrombin inhibitor bivalirudin during primary angioplasty had ... rate of major bleeding, and a lower mortality rate ...
... May 22, Shire plc (LSE: SHP)(NASDAQ: SHPGY ... High Court approved,the scheme of arrangement between Shire ... The scheme, which becomes effective on 23 May ... Limited (LSE: SHP,NASDAQ: SHPGY) becoming the new holding ...
... international team of scientists surveying the waters of the ... has discovered for the first time high levels of ... raising concern for marine ecosystems from Canada to Mexico. ... research vessel, also discovered that this corrosive, acidified water ...
Cached Biology News:Findings released from 1 of the largest percutaneous coronary intervention trials ever 2Court Approves Scheme of Arrangement 2Court Approves Scheme of Arrangement 3Pacific coast turning more acidic 2Pacific coast turning more acidic 3
... When Ambion introduced the highly potent TURBO DNase ... new standard was set in DNA removal capabilities. ... DNase I that is much more efficient than ... amounts of unwanted DNA. TURBO DNase binds DNA ...
...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: